Lilly's Obesity Pill Shows Promising Results in Clinical Trials.

Eli Lilly's experimental pill, orforglipron, led to a 14.7% weight loss on the highest dose in a 36-week trial, matching the estimates given by the company in an investor call last year. The mid-stage results were presented at the American Diabetes Association conference and published in the New England Journal of Medicine. The drug's potential for even greater weight loss over a longer treatment period was suggested as participants' weight loss had not plateaued by the end of the trial, heating up the competition among drugmakers to develop an effective oral obesity therapy.